

DEPARTMENT OF REGULATORY AGENCIES
PRESCRIPTION DRUG AFFORDABILITY BOARD

3 CCR 702-9

Part 4 UPPER PAYMENT LIMITS

4.3 Upper Payment Limit for Enbrel (Etanercept)

A. Authority

The statutory authority for this rule is sections 10-16-1403(1)(c), 10-16-1403(5), 10-16-1407(1)(a), and 10-16-1407(5), 10-16-1407(6), C.R.S.

B. Scope and Purpose

The purpose of this rule is to establish an upper payment limit for the prescription drug, Enbrel (Etanercept), pursuant to section 10-16-1407, C.R.S., and part 4.1 of these rules. The Board performed an affordability review of Enbrel and determined it was unaffordable for Colorado consumers pursuant to section 10-16-1406, C.R.S., and part 3 of these rules.

C. Applicability

See section 10-16-1407(5), C.R.S., and Division of Insurance Regulation 3 CCR 702-9, Part 4.2.C.

D. Definitions

“Prescription drug” shall have the same meaning as found at section 10-16-1401(19), C.R.S.

“Upper payment limit” shall have the same meaning as found at section 10-16-1401(23), C.R.S.

E. Upper Payment Limit

The upper payment limit for Enbrel (Etanercept) is set at \$600.00 per 50 milligram/milliliter unit. This price per unit will apply to all formulations of Enbrel. The price per unit will be reviewed annually.

F. Severability

If any portion of these rules is found to be invalid, the remaining portion of the rules shall remain in force and effect.

G. Effective Date

This regulation shall become effective on January 1, 2027.

H. History

New regulation effective January 1, 2027.